Nektar Therapeutics Stock News

Price T Rowe Associates Inc. MD reduced its position in shares of Nektar Therapeutics (NASDAQ:NKTR) by 3.4% in the second quarter, HoldingsChannel.com reports. The firm owned 513,965 shares of the biopharmaceutical companys stock after selling 18,199 shares during the period. Price T Rowe Associates Inc. MDs holdings in Nektar Therapeutics were worth $8,820,000 at the []

Nektar Therapeutics (NASDAQ:NKTR)s stock price reached a new 52-week low on Thursday . The stock traded as low as $12.17 and last traded at $12.23, with a volume of 8395 shares changing hands. The stock had previously closed at $12.85. Several equities analysts have weighed in on NKTR shares. Bank of America started coverage on []

Related Stocks: NKTR ,

Global NK Cell Therapy Market report 2021 focuses on the industry status, future forecast, growth opportunity, key market, and key players. This study is very useful information for new and growing companies to display themselves in the market. Additionally, the

Millennium Management LLC lifted its position in shares of Nektar Therapeutics (NASDAQ:NKTR) by 434.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 576,389 shares of the biopharmaceutical companys stock after buying an additional 468,486 shares during the period. Millennium Management LLC []

Wall Street analysts expect that Nektar Therapeutics (NASDAQ:NKTR) will announce earnings per share (EPS) of ($0.82) for the current fiscal quarter, Zacks Investment Research reports. Six analysts have issued estimates for Nektar Therapeutics earnings, with estimates ranging from ($0.89) to ($0.74). Nektar Therapeutics reported earnings of ($0.65) per share during the same quarter last year, []

Nektar Therapeutics (NASDAQ:NKTR) price closed lower on Friday, November 12, dropping -1.40% below its previous close. >> 7 Top Picks for the Post-Pandemic Economy > 7 Top Picks for the Post-Pandemic Economy

Charles Schwab Investment Management Inc. increased its holdings in shares of Nektar Therapeutics (NASDAQ:NKTR) by 2.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 891,265 shares of the biopharmaceutical companys stock after buying an additional 19,850 shares during the quarter. Charles []

Friday, November 5th's trading of NKTR (NKTR) was - in our opinion - a short/manipulator shakedown of epic proportions. Nektar's 3Q conference call was clumsily executed but contained strong data and

SAN FRANCISCO, Nov. 9, 2021 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today that it will host a webcast analyst and investor conference call with a cancer specialist and Nektar mana

Nektar (NKTR) reports mixed third-quarter 2021 results. The company remains on track to report top-line data from three registrational studies on bempegaldesleukin in the first half of 2022.

Nektar Therapeutics (NKTR) CEO Howard Robin on Q3 2021 Results - Earnings Call Transcript

Nektar (NKTR) delivered earnings and revenue surprises of 12.50% and -16.57%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

SAN FRANCISCO, Oct. 26, 2021 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2021 on Thursday, November 4, 2021, after the close of U.S

Short covering has accelerated dramatically as the price bottomed and recovered.